Researchers at University of Sydney’s NHMRC Clinical Trials Centre, RMIT University, and WEHI in Australia have developed a diagnostics blood test that could improve deciding which ovarian cancer patients should receive a PARP inhibitor. The test was developed during a four-year clinical trial conducted across 15 Australian hospitals, called SOLACE2 trial, while the researchers were investigating whether immune system “priming” could enhance the effectiveness of PARP inhibitor therapy.

The blood-based test, detailed in Nature Communications , measures immune biomarkers that signal the readiness of the immune system to recognize and attack cancer cells, and is potentially more accurate than using a DNA-based homologous recombination deficiency (HRD) test used, which is currently rout

See Full Page